Brought to you by 
Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center
05 Oct 2021
Executive Summary
Lion Biotechnologies Inc. (cancer immunotherapies) licensed exclusive rights to two patent-pending tumor infiltrating lymphocyte (TIL) technologies from the University of South Florida’s H. Lee Moffitt Cancer Center & Research Institute. The license continues until the last patent related to the technologies expires, or 20 years, whichever comes first.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice